Medovate is breaking into the US market by launching its FDA approved SAFIRA regional anaesthesia innovation at ASRA 2020.
SAFIRA (SAFer Injection for Regional Anaesthesia) aims to advance standard clinical practice with regards to regional blocks in a number of ways. The device contains a safety feature that helps prevent anaesthetic being injected at unsafe pressures, aiming to reduce the risk of significant or peripheral nerve damage.
The device makes the regional anaesthesia process a one-person procedure by a single anaesthetist (current processes require two operators, an anaesthetist and a technician), he or she has full control throughout.
At ASRA 2020, US clinicians will have their first opportunity to see Medovate’s SAFIRA in action. The company will be running demonstrations and allowing experts in regional anaesthesia and pain medicine to view the device up close.
To extend its reach into the US market, Medovate has also joined the Association of British Healthcare Industries (ABHI) US Accelerator. This 12-month programme is designed to support medical device companies seeking to access US buyers and will allow Medovate to plug into ABHI’s expertise and connections within the US, including major hospitals and Group Purchasing Organisations (GPOs).
SAFIRA has been designed so that its application for regional anaesthesia procedures is the same in all markets, meaning that no additional modifications are required for the US or any other market.
Stuart Thomson, managing director, Medovate, said: “Launching in the US is a statement both of our ambitions for international expansion and of the confidence we have in the medtech devices within our portfolio. With a healthy innovation pipeline, including a ground-breaking device for airway management to come soon, we hope that the launch of SAFIRA is the first in a series of exciting new developments for Medovate this year.”
The 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA), takes place in San Francisco on 23-25 April.
